Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 120   

Articles published

4502 4,714.00 +9.00 (0.19%)
price chart
Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD ...
BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced the commencement of the cash tender offer by its wholly-owned indirect subsidiary, Kiku Merger Co.
ARIAD Investigated Over Proposed Sale of Company to Takeda  Pharmaceutical Processing
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for ...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Global 100 Most Sustainable Corporations in the World Index.
Form SC TO-C ARIAD PHARMACEUTICALS Filed by: TAKEDA PHARMACEUTICAL CO LTD
This filing relates solely to preliminary communications made before the commencement of a tender offer by Kiku Merger Co., Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, ...
Takeda is buying Ariad Pharmaceuticals in a $5.2 billion deal
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) (“Ariad”) today announced that they have entered into a definitive agreement under which Takeda will ...
Takeda Pays 2012 Price For 2017 Model ARIAD  Seeking Alpha
Investor Watch: Checking in on Shares of Takeda Pharmaceutical Company Limited ...
Investors might be looking to check on Free Cash Flow metrics for Takeda Pharmaceutical Company Limited (TSE:4502). Free cash flow represents the amount of cash that a company has generated for shareholders after paying off expenses and investing in ...
Takeda and Ovid Therapeutics Announce Innovative Clinical Development and ...
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
Takeda and Ovid Therapeutics to Collaborate on Pediatric Epilepsy Drug  Pharmaceutical Processing
Takeda, Ovid to Co-Develop Rare Pediatric Epilepsy Candidate TAK-935  Genetic Engineering & Biotechnology News (blog)
Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing ...
KONSTANZ, Germany & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine ...
Takeda Takes the Hard Road
But Takeda Pharmaceutical Co. Ltd.'s purchase of cancer drugmaker Ariad Pharmaceuticals Inc. for about $4.66 billion -- at a 75 percent premium to Ariad's Friday share price, according to Monday's announcement -- was an unexpected kick-off.
Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T ...
BRISBANE, Calif. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Maverick Therapeutics Inc., an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that they have entered a ...
Valeant: Forget About Acquisition. Takeda Has Bought ARIAD
Takeda was planning an acquisition; however, instead of buying Valeant's Salix, the Japanese gastro-pharma bought ARIAD (NASDAQ:ARIA) - an oncological business with a strong pipeline and significant pricing power.